Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. ResMed (NYSE:RMD) is seeing growing use of wearable devices for sleep apnea pre ...
ResMed’s recurring revenue model leverages device sales, consumables, and SaaS, with growth driven by rising diagnosis and ...
As Philips reaches a consent decree agreement with the FDA that will temporarily suspend its sales of sleep therapy devices in the U.S., competitor ResMed, meanwhile, is ramping up its product ...
ResMed is on a mission to cement the lead it’s built while competitor Philips has been out of the CPAP machine-making game. That process of building out its market share for the long-term has recently ...
Few observers think of CPAP machines as common fare where the med-tech patent wars are concerned, but Resmed Corp. recently came away with a win in litigation that resulted in the nullification of the ...
Connected sleep devicemaker ResMed today released the AirSense 11, its latest CPAP machine iteration, which includes a host of new features to treat obstructive sleep apnea. The new machine has many ...
The new AirTouch™ N30i tube-up nasal mask for CPAP combines softness, breathability, and a high-performance, durable seal to provide exceptional comfort SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ...
ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business model. I rate RMD a strong sell due to the imminent threat from Apnimed's ...
ResMed (NYSE:RMD) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results